Nexalis Therapeutics Limited (ASX:NX1)

Nexalis Therapeutics Revenue

In the year 2025, Nexalis Therapeutics had annual revenue of 986.43K AUD with 145.50% growth. Nexalis Therapeutics had revenue of 429.32K in the half year ending December 31, 2025, a decrease of -43.94%.

• Revenue: 986.43K
• Revenue Growth: +145.50%
• P/S Ratio: 6.16
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 6.07M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	986.43K	584.62K	145.50%
Dec 31, 2024	401.81K	-802.24K	-66.63%
Dec 31, 2023	1.20M	1.18M	4,755.02%
Dec 31, 2022	24.80K	-156.94K	-86.35%
Dec 31, 2021	181.74K	159.61K	721.35%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

May 7, 2026

Data Sources Report a data error